Moreover, in untreated CLL with TP53 mutations, there is a subset of patients with indolent clinical courses, which suggests that other disease- and/or patient-related parameters may alter the impact of TP53 disruption (67, 68). Here, TP53 is linked to B-cell chronic lymphocytic leukemia.